Vaibhav Agrawal, M.D., M.B.A.
Hematologist-Oncologist
4.9 (27 RATINGS)
Clinical Expertise
Hematology & Hematopoietic Cell Transplantation
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Research Area
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Hematopoietic Stem Cell Transplantation
Post-transplant Relapse
Graft-versus-host Disease
Immunotherapy And Cellular Therapy
Adolescent And Young Adult Oncology
Cancer Survivorship
Health Care Quality And Delivery
Languages
Appointments
Assistant Professor, Division Of Leukemia, Department Of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Vaibhav Agrawal, M.D., M.B.A., is no stranger to City of Hope. Beginning in his senior year of high school and throughout college, Dr. Agrawal spent every summer at City of Hope’s laboratories and returned during medical school to study bone marrow transplantation. He is driven to make a difference in the fight against a disease he’d endured as a child.
When he was 4 years old, Dr. Agrawal was stricken with acute lymphoblastic leukemia, an experience that motivated him to become a hematologist/oncologist. His passion for research grew as well. In addition to his medical degree, he holds advanced degrees in health care law, administration and management.
Dr. Agrawal received his M.D. from Chicago Medical School. He did his residency at Geisinger Medical Center and completed fellowships at Indiana University, and Stanford University. He focuses his research on improving the outcomes of stem cell transplants and preventing graft-versus-host disease. “I have followed the achievements of City of Hope,” he said, “and continue to remain enamored by the culture and excellent outcomes provided by the institution.”
2014, Masters of Jurisprudence (M.J.), Health Care Law, Loyola University Chicago School of Law, Chicago, IL
2013, Doctor of Medicine (M.D.), Chicago Medical School, Rosalind Franklin University of Medicine and Science North Chicago, IL
2011, Masters of Science Healthcare Administration (M.S.H.A.), College of Health Professions, Rosalind Franklin University of Medicine and Science, North Chicago, IL
2011, Masters of Business Administration (M.B.A.), Healthcare Management, Loyola University Quinlan School of Business, Chicago, IL
2021, Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
2020, Hematology-Oncology, Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN
2016-2017, Chief Resident, Internal Medicine-Pediatrics, Geisinger Medical Center, Danville, PA
2021-Present, Assistant Professor, Division of Leukemia, Department of
Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California
2011, Beta Gamma Sigma
2006, Clinton E. Stryker Distinguished Service Award
2006, Leadership Academy Scholarship
2003, Phillip Danforth Armour Scholarship
2003, ABC-7 Los Angeles Cool Kid
American Association for Physician Leadership
Society of Physician Entrepreneurs
American Society of Clinical Oncology
American Society of Hematology
American Society for Transplantation and Cellular Therapy
- Methany L, Callander NS, Hall AC, Zhang MJ, Bo-Subait K, Wang HL, Agrawal V, et al. Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther. 2021 Aug; S2666-6367(21)01146-5.doi: 10.1016/j.jtct.2021.08.010.
- Agrawal V, Abonour R, Abu Zaid M, Althouse SK, et al. Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood stem cell transplantation. Cancer. 2021 Oct; 127(20):3751-3760.
- Agrawal V, Ranganath P, Ervin KD, et al. Effect of Sirolimus Levels Between Days 11 and 20 After Allogeneic Stem Cell Transplantation on the Risk of Hepatic Sinusoidal Obstruction Syndrome. Bone Marrow Transplant. 2021 Jan;56(1):121-128.
- Munshi PN, Vesole D, Jurczysyn A, Zaucha JM, St. Martin A, Davilla O, Agrawal V, et al. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020 Dec; 126(23):5077-5087.
- Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala L, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, et al. Risk factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation using Post-Transplantation Cyclophosphamide. Biol Blood Marrow Transplant. 2020 Aug; 26(8):1459-1468.
- Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, et al. A multi-institution comparison of mitoxantrone, etoposide, and cytarabine vs. high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am. J. Hematol. 2020 Aug; 95(8):937-943.
- Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 Jul; 4(13):3180-3190.
- Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, et al. Composite GRFS and CRFS Outcomes after Adult Alternative Donor HCT. J. Clin. Oncol. 2020 Jun; 38(18):2062-2076.
- Agrawal V, Brinda BJ, Farag SS. Histoplasma capsulatum infection in an allogeneic hematopoietic stem cell transplant receiving voriconazole prophylaxis. Case Rep. Hematol. 2020; 2020:8124137.
- Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, et al. Vaccine and Cell Based Therapeutics in Acute Myeloid Leukemia. Curr. Cancer Drug Targets. 2020 May; 20(7):473-489.
- Agrawal V, Dinh PC Jr., Fung C, Monahan PO, et al. Adverse Health Outcomes among US Testicular Cancer Survivors after Cisplatin-Based Surgical Management. JNCI Cancer Spectr. 2019 Oct;4(2):pkz079.
- Agrawal V, Adra N. Salvage therapy for relapsed testicular cancer: a need for consensus. Future Oncol. 2019 Dec; 15(34):3881-3884.
- Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, et al. Impact of T cell dose on T cell-replete HLA matched allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2019 Sep; 25(9):1875-1883.
- Kilari D, D’Souza A, Fraser R, Qayed M, Davilla O, Agrawal V, et al. Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades. Biol Blood Marrow Transplant. 2019 Jun; 25(6):1099-1106.
- Parikh SH, Satwani P, Ahn KW, Sahr NA, Fretham C, Abraham AA, Agrawal V, et al. Survival trends in infants undergoing allogeneic hematopoietic cell transplant. JAMA Pediatr. 2019 May; 173(5):e190081.
- Inamoto Y, Petricek I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovo A, Schears R, Shaha A, Agrawal V, et al. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the late effects and quality of life working committee of the CIBMTR and transplant complications working party of the EBMT. Bone Marrow Transplant. 2019 May; 54(5):648-661.
- Salwei ME, Carayon P, Hundt AS, Hoonaker P, Agrawal V, et al. Role network measures to assess healthcare team adaptation to complex situations: the case of venous thromboembolism prophylaxis. Ergonomics. 2019 Apr. 62(7): 864-879.
- Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, Aljurf M, Agrawal V, et al. Effect of conditioning regimen dose reduction in obese patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019 Mar; 25(3):480-487.
- Scott EC, Hari P, Kumar S, Fraser R, Davilla O, S N, Gale RP, Diaz MA, Agrawal V, et al. Staging systems for newly diagnosed myeloma patients undergoing autologous hematopoietic cell transplantation: the revised international staging system shows the most differentiation between groups. Biol Blood Marrow Transplant. 2018 Dec; 24(12):2443-2449.
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
5.0
Recommend this provider office
4.9
Show respect for what you say
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.8
Spend enough time with you
4.8
Rate provider 0-10
4.7
Know important info medical history
Reviews
09/25/22
This was life saving, would recommend to everyone - Verified patient
06/18/22
Dr. Agrawal is fantastic! He saved my life so far! - Verified patient